Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.
Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.
TranscriptWhy is it important to treat neuroendocrine tumors with a multidisciplinary team?
I cannot emphasize enough how important it is to have a multidisciplinary team for neuroendocrine tumors (NETs). You have to have a NET-focused pathologist to review the slides of the patient, because often, the diagnosis can change slightly. When we have a pathologist reviewing that that specializes in NETs, then you have to have a good radiologist helping to read the films.
Then, you have to have your surgeon or surgical oncologist looking and evaluating the patient with you, because even in the setting of stage 4 disease or metastatic disease, we can still offer surgery to these patients in many occasions. They surgeries can even be a curative intent in putting the patients in remission for a very long time, or it could be offered to improve the quality of life, because some of these patients are so symptomatic that the bulking of the disease can make wonders for the quality of life.
We also have to have a nuclear medicine physician with us because now with the upcoming use of peptide receptor radionuclide therapy, you know, our colleagues from nuclear medicine are extremely essential for the treatment of NETs. We have to have the help our endocrinologist to help with some of the issues that come with having a NET patient. I haven’t even mentioned the fact that we need the help of the gastroenterologist to diagnosis the disease, because sometimes we have to do 2 endoscopy procedures, but also with helping managing some of the most challenging issues of these patients, including diarrhea, for example.
So, these are just a few examples of how a patient with NETs should be taken care of by a multidisciplinary team.
How important is it to engage patients and their families in their care so that they understand their treatment and their diagnosis?
So, it’s very important to educate patients and their families in terms of the new diagnosis of NETs. When patients come to the clinic to me, I typically explain what a NET is. I try to make the comparison, to some extent, I compare the Steve Jobs pancreatic cancer versus the Patrick Swayze pancreatic cancer. That gives a sort of visual understanding of the difference between both diseases.
I try to explain the natural history of the disease as much as the capability of the patient to understand the differences. And then I also redirect patients to reliable sources of information that we have on the internet, from the different NET organization that we have with the Carcinoid Foundation, we have the Healing NET Foundation. The NET Research Foundation also has some information for patients. I think all of these are very important. There’s also amazing supportive group organizations out there. They are extremely reliable and supportive to patients, so I tend to direct my patients to these type of organizations as well.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More